hepat
e
viru
hev
zoonot
pathogen
sever
speci
includ
human
be
pig
rodent
report
suscept
date
vaccin
develop
hev
still
need
improv
structur
gene
encod
capsid
protein
high
sequenc
conserv
found
across
hev
genotyp
potenti
candid
exploit
possibl
use
rna
interfer
rnai
strategi
hev
infect
four
small
interfer
rna
sirna
duplex
target
gene
construct
challeng
hev
infect
rnai
perform
cell
realtim
quantit
polymeras
chain
reaction
realtim
qpcr
western
blot
assay
demonstr
four
hev
specif
sirna
capabl
protect
cell
hev
infect
high
specif
effici
result
suggest
rnai
potent
antihev
infect
prophylaxi
strategi
elsevi
bv
right
reserv
moreov
immun
escap
also
occur
new
virul
hev
variant
evolv
case
sever
acut
respiratori
syndrom
coronaviru
sarscov
evolv
human
coronaviru
lin
et
al
saif
respect
mutat
event
cell
cultur
report
primari
propag
consecut
passag
report
lorenzo
et
al
tanaka
et
al
particularli
worrisom
paper
rna
interfer
rnai
use
way
circumv
issu
regard
vaccin
high
specif
effici
rnai
phenomenon
small
doublestrand
rna
molecul
induc
sequencespecif
degrad
homolog
singlestrand
rna
hannon
rnai
power
tool
investig
gene
function
specif
suppress
particular
mrna
employ
therapeut
studi
human
diseas
includ
cancer
neurogen
diseas
viral
infecti
diseas
similar
strategi
capabl
reduc
significantli
sarscov
replic
akerstrom
et
al
hepat
c
viru
mrna
accumul
liu
et
al
suggest
rnai
may
one
use
antivir
therapi
strategi
current
investig
field
rnai
expand
much
research
report
mani
gene
interest
includ
oncogen
viral
gene
indic
success
silenc
cell
anim
model
akerstrom
et
al
kirchhoff
kleinman
et
al
liu
et
al
also
number
clinic
trial
use
rnai
strategi
includ
one
agerel
macular
degener
amd
kleinman
et
al
applic
expect
hev
use
studi
character
genotyp
hev
genbank
access
isol
swine
fece
shanghai
china
use
templat
revers
transcript
nest
polymeras
chain
reaction
pcr
rtnpcr
amplifi
hev
gene
gene
encod
major
structur
capsid
protein
hev
riddel
et
al
extern
forward
primer
revers
primer
respect
intern
forward
primer
revers
primer
respect
rtnpcr
analysi
conduct
use
amv
revers
transcriptas
xl
kit
rtpcr
takara
tokyo
japan
accord
manufactur
direct
rtpcr
protocol
perform
includ
revers
transcript
phase
min
two
microlit
cdna
synthes
amplifi
nest
pcr
min
follow
min
repeat
cycl
pcr
product
detect
electrophoresi
agaros
gel
contain
mgml
ethidium
bromid
amplifi
dna
fragment
insert
multiclon
site
eukaryot
express
vector
clontech
gift
dr
wei
liu
contain
report
gene
enhanc
green
fluoresc
protein
egfp
use
standard
clone
procedur
restrict
site
ecori
bamhi
egfp
gene
locat
downstream
target
gene
recombin
plasmid
name
four
nt
sirna
dna
end
correspond
target
gene
fig
design
accord
qiagen
guidelin
http
wwwqiagencom
sirna
duplex
design
use
hiperform
design
algorithm
licens
novarti
ag
integr
stringent
inhous
homolog
analysi
tool
highestrank
sirna
duplex
gener
algorithm
chosen
repres
best
combin
activ
specif
scrambl
sirna
construct
random
sequenc
heterolog
hev
sequenc
serv
neg
control
identifi
specif
hev
sirna
tabl
synthes
nonmodifi
sirna
dilut
rnasefre
buffer
obtain
mm
solut
solut
denatur
heat
min
incub
min
either
use
immedi
store
rnasefre
environ
human
lung
carcinoma
atcc
va
usa
cell
line
use
studi
maintain
describ
previous
huang
et
al
cell
trypsin
transfer
ml
antibioticfre
growth
medium
plate
well
cell
cultur
h
transfect
one
microgram
scrambl
sirna
sens
r
uuc
ucc
gaa
cgu
guc
acg
u
antisens
r
acgugacacguucggagaa
recombin
plasmid
dilut
ml
serumfre
dmem
medium
mix
gentli
ml
five
nm
sirna
ml
lipofectamin
invitrogen
ca
usa
accord
manufactur
instruct
ml
serumfre
dmem
medium
min
cotransfect
cell
meanwhil
sirna
either
cotransfect
pegfp
vector
transfect
alon
cell
test
interferon
respons
optim
combin
four
paramet
cell
line
includ
highest
transfect
effici
lowest
nonspecif
effect
condit
effici
deliveri
sirna
concentr
lipofectamin
first
determin
preliminari
experiment
four
six
hour
posttransfect
cultur
medium
replac
fresh
complet
medium
cell
incub
h
mrna
detect
h
protein
detect
determin
transfect
effici
egfp
fluoresc
intens
transfect
cell
monitor
invert
fluoresc
microscop
nikon
tokyo
japan
realtim
qpcr
analysi
effici
suppress
hev
gene
variou
hev
specif
sirna
evalu
fluoresc
microscopi
realtim
qpcr
western
blot
specif
inhibit
confirm
cotransfect
recombin
plasmid
scrambl
sirna
hev
success
cultur
cell
previous
describ
huang
et
al
hev
infect
challeng
cell
transfect
sirna
scrambl
sirna
describ
previous
h
viru
challeng
viral
challeng
perform
previous
describ
huang
et
al
tanaka
et
al
viru
viral
count
ml
calcul
viral
genom
titer
determin
realtim
quantit
pcr
li
et
al
kasorndorkbua
et
al
inocul
cell
cpe
observ
daili
cell
harvest
h
postinocul
cpe
observ
realtim
qpcr
analysi
downstream
target
h
western
blot
assay
cell
per
well
seed
plate
incub
describ
except
amount
sirna
viruspegfp
well
onefourth
plate
fortyeight
hour
postinocul
virus
cultur
medium
remov
cell
lyse
freezethaw
three
time
total
rna
extract
trizol
invitrogen
ca
usa
accord
manufactur
direct
revers
transcrib
cdna
use
amv
revers
transcriptas
xl
kit
synthes
first
strand
cdna
ml
ad
templat
realtim
qpcr
use
sybr
premix
ex
taq
tm
perfect
realtim
takara
tokyo
japan
accord
manufactur
direct
forward
primer
nt
revers
primer
nt
mixtur
react
follow
repeat
cycl
product
expect
bp
housekeep
gene
gapdh
serv
load
control
forward
primer
gapdh
revers
primer
pcr
protocol
cell
except
repeat
cycl
realtim
qpcr
analysi
perform
abi
prism
realtim
pcr
system
abi
ct
usa
procedur
perform
triplic
data
express
mean
ae
sd
infect
cell
harvest
h
postinocul
lyse
buffer
mm
trishcl
ph
mm
nacl
sodium
azid
triton
mg
ml
aprotinin
mgml
pmsf
equival
amount
total
protein
separ
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
transfer
onto
nitrocellulos
membran
block
nonspecificbind
site
skim
milk
membran
incub
primari
antibodi
overnight
primari
antibodi
use
experiment
rabbit
polyclon
antihev
abr
ca
usa
dilut
rabbit
polyclon
antigapdh
load
control
proteintech
group
co
usa
dilut
wash
tb
buffer
blot
incub
hrp
conjug
goat
antirabbit
igg
promega
wi
usa
dilut
room
temperatur
h
band
expos
xray
film
supersign
west
pico
trial
kit
pierc
rockford
usa
bp
fragment
hev
nt
amplifi
rtnpcr
introduc
vector
restrict
site
ecori
bamhi
yield
recombin
plasmid
identifi
digest
restrict
enzym
ecori
bamhi
sequenc
cell
transfect
recombin
plasmid
sirna
observ
fluoresc
microscop
h
posttransfect
fig
effici
transfect
confirm
highli
express
report
gene
egfp
protein
fluoresc
assay
show
obviou
reduct
effect
induc
hev
specif
sirna
except
scrambl
one
fig
suggest
high
effici
specif
inhibit
effect
sirna
achiev
studi
effect
sirna
protect
cell
hev
destruct
mt
assay
perform
od
valu
mean
ae
sd
solut
well
treat
sirna
shown
fig
absorb
nm
directli
proport
number
live
cell
cultur
number
live
cell
well
treat
hev
specif
sirna
treat
scrambl
sirna
untransfect
control
cell
interferon
respons
observ
cell
transfect
sirna
alon
cotransfect
pegfp
vector
reduct
mrna
level
hev
evalu
realtim
qpcr
percentag
hev
mrna
cell
previous
transfect
sirna
cell
inocul
hev
alon
calcul
accord
pfaffl
method
pfaffl
suppress
hev
mrna
h
postinocul
decreas
cell
transfect
nmwell
sirna
respect
signific
chang
note
cell
transfect
scrambl
sirna
fig
gapdh
transcript
level
rare
chang
either
untransfect
transfect
cell
data
shown
optim
inhibitori
effect
sirna
hev
transcript
viral
mrna
yield
reduct
assay
conduct
transfect
cell
sirna
indic
dose
shown
fig
transfect
nm
well
sirna
induc
approxim
reduct
viral
mrna
howev
dosag
sirna
increas
hev
mrna
decreas
fig
sirna
cotransfect
cell
express
hev
protein
observ
h
posttransfect
hev
specif
sirna
induc
obviou
reduct
wherea
express
level
egfp
protein
cotransfect
scrambl
sirna
show
signific
chang
sirna
cotransfect
pegfp
vector
test
interferon
respons
recombin
plasmid
transfect
alon
pegfp
pegfp
vector
cotransfect
pegfp
pegfp
vector
cotransfect
scrambl
sirna
recombin
plasmid
cotransfect
scrambl
sirna
recombin
plasmid
cotransfect
recombin
plasmid
cotransfect
recombin
plasmid
cotransfect
recombin
plasmid
cotransfect
pictur
taken
h
posttransfect
nikon
fluoresc
microscop
fig
protect
cell
hev
infect
sirna
rnai
inhibit
cell
growth
determin
mt
assay
cell
transfect
hev
specif
sirna
scrambl
sirna
untransfect
infect
cell
serv
control
absorb
read
nm
result
obtain
triplic
well
od
valu
shown
mean
ae
sd
amount
sirna
reach
nmwell
highest
inhibit
hev
transcript
obtain
data
indic
suppress
hev
transcript
sirna
dosedepend
analyz
effici
suppress
hev
protein
synthesi
sirna
cell
collect
western
blot
analysi
cell
infect
hev
express
expect
kda
protein
band
uninfect
cell
show
protein
band
react
antihev
antibodi
western
blot
show
hev
put
structur
protein
express
reduc
significantli
cell
transfect
hev
specif
sirna
fig
compar
cell
infect
hev
alon
transfect
scrambl
sirna
fig
scrambl
gapdh
use
load
control
experi
conclus
result
demonstr
highli
effici
inhibit
hev
transcript
hev
specif
sirna
cell
obtain
hev
major
caus
enter
transmit
acut
hepat
adult
highli
lethal
pregnant
women
hev
gene
highli
conserv
four
genotyp
import
structur
region
viru
evid
epidemiolog
anim
transmiss
vaccin
studi
indic
gene
suitabl
region
hev
treatment
studi
therefor
hev
gene
chosen
target
sirna
gene
silenc
current
studi
rna
interfer
show
great
promis
antivir
therapi
sinc
discoveri
mammalian
cell
elbashir
et
al
applic
vitro
vivo
shown
new
effici
approach
inhibit
viral
infect
howev
also
shown
studi
differ
sirna
sequenc
differ
interfer
efficaci
depend
characterist
target
rna
includ
local
rna
fold
access
sirnabind
site
target
rna
kurreck
shao
et
al
highest
potenti
effici
interfer
consid
high
knockdown
avoid
degrad
untarget
gene
offtarget
effect
fewer
sirna
ladunga
rna
interfer
viral
infect
focu
numer
studi
liu
et
al
mungal
et
al
effect
specif
interfer
hev
transcript
obtain
cell
current
studi
rnai
exquisit
specif
seek
target
determin
exclus
protect
hepat
e
viru
hev
specif
sirna
capabl
prevent
hev
infect
cell
antivir
activ
demonstr
mrna
transcript
level
realtim
qpcr
protein
express
level
western
blot
find
indic
protocol
may
effect
antivir
strategi
protect
host
cell
viral
invas
sirna
effect
vitro
howev
mani
obstacl
applic
rnai
vivo
therapi
main
obstacl
prevent
degrad
sirna
avoid
side
effect
host
induc
sirna
couzin
grimm
kay
mention
toxic
sirna
shrna
express
vector
vitro
vivo
cell
apoptosi
observ
vector
introduc
high
concentr
although
rnai
pathway
promis
treatment
cancer
viru
hepat
therapi
seriou
safeti
issu
first
need
address
mcbride
et
al
need
focu
decreas
toxic
accompani
sirna
treatment
conclus
present
studi
demonstr
hev
specif
sirna
could
specif
effect
suppress
hev
transcript
translat
cell
result
indic
rnai
potenti
antivir
therapi
suppress
hev
infect
studi
requir
determin
effect
safeti
rna
interfer
mean
protect
hev
infect
vivo
